MiNK Therapeutics, Inc.
INKT
$14.57
-$0.33-2.22%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.85M | 1.27M | 808.90K | 1.16M | 1.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -62.70K | 180.90K | -- |
| Total Operating Expenses | 3.69M | 2.53M | 4.37M | 1.88M | 2.90M |
| Operating Income | -3.69M | -2.53M | -4.37M | -1.88M | -2.90M |
| Income Before Tax | -4.24M | -2.77M | -2.46M | -1.81M | -2.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.24M | -2.77M | -2.46M | -1.81M | -2.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.24M | -2.77M | -2.46M | -1.81M | -2.70M |
| EBIT | -3.69M | -2.53M | -4.37M | -1.88M | -2.90M |
| EBITDA | -3.64M | -2.48M | -4.26M | -1.82M | -2.86M |
| EPS Basic | -1.06 | -0.70 | -0.62 | -0.46 | -0.73 |
| Normalized Basic EPS | -0.61 | -0.41 | -0.65 | -0.29 | -0.46 |
| EPS Diluted | -1.06 | -0.70 | -1.25 | -0.46 | -0.73 |
| Normalized Diluted EPS | -0.61 | -0.41 | -0.65 | -0.29 | -0.46 |
| Average Basic Shares Outstanding | 3.98M | 3.97M | 3.96M | 3.95M | 3.71M |
| Average Diluted Shares Outstanding | 3.98M | 3.97M | 3.96M | 3.95M | 3.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |